|
Protocol ID |
Official Title |
PI Name |
Lead CRC |
Disease Site |
Phase |
|
CA01800f (Fraction-RCC) ClinicalTrials.gov: NCT02996110 |
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology Study of Participants with Advanced Renal Cell Carcinoma | J. Parikh | Kelly Jenkins | Renal Cell Carcinoma | II |
|
CX-839-008 ClinicalTrials,gov: NCT03428217 |
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib vs. Placebo with Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma | J. Parikh | Kelly Jenkins | Renal Cell Carcinoma | II |
| SGN22E-001 ClinicalTrials.gov: NCT03219333 | A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Recived Immune Checkpoint Inhibitor (CPI) Therapy | J. Parikh | Kelly Jenkins | Urothelial Cancer | II |
|
MK3475-641 ClinicalTrials.gov: NCT03834493 |
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) | J. Parikh | Kelly Jenkins | Prostate Cancer | III |
|
MK3475-921 ClinicalTrials.gov: NCT03834506 |
A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE921 | J. Parikh | Kelly Jenkins | Prostate Cancer | III |
|
MK7339-010 ClinicalTrials.gov: NCT03834519 |
A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010) | J. Parikh | Kelly Jenkins | Prostate Cancer | III |
